Lauren Rudy1, Christine Maheu2, Annett Körner3, Sophie Lebel4, Céline Gélinas5. 1. Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada. 2. Ingram School of Nursing, McGill University, Montreal, Quebec, Canada. 3. Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada. 4. School of Psychology, University of Ottawa, Ottawa, Ontario. 5. Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: Fear of cancer recurrence (FCR) is characterized by the fear, worry or concern that cancer will come back or progress. The negative effects associated with FCR are consistently identified by cancer survivors as one of their most prominent unmet needs. Current measures of FCR can be long, complex and burdensome for survivors to complete. The objective of the present study is to develop and validate a one-item measure of FCR. METHODS: The ability of the FCR-1 to detect change in FCR over time was analyzed using a repeated-measures ANOVA and paired-samples t-tests. Pearson correlations were used to measure the concurrent, convergent and discriminant validity of the FCR-1, and a ROC analysis was conducted to determine an optimal clinical cut-off score. RESULTS: The FCR-1 was found to be responsive to change in FCR over time. It demonstrated concurrent validity with the FCRI (r = .395, P = .010), and convergent validity with the Mishel Uncertainty in Illness Scale (r = .493, P = .001) and the Reassurance Questionnaire (r = .325, P = .044). Discriminant validity was confirmed when the FCR-1 did not significantly correlate with unrelated measures. A ROC analysis pinpointed an optimal clinical cut-off score of 45.0. CONCLUSIONS: The FCR-1 is a promising tool that can be incorporated in clinical and research settings. Due to its brevity, the care needs of highly distressed patients can be met quickly and efficiently. In research settings, the FCR-1 can reduce the cognitive burden experienced by survivors.
OBJECTIVE: Fear of cancer recurrence (FCR) is characterized by the fear, worry or concern that cancer will come back or progress. The negative effects associated with FCR are consistently identified by cancer survivors as one of their most prominent unmet needs. Current measures of FCR can be long, complex and burdensome for survivors to complete. The objective of the present study is to develop and validate a one-item measure of FCR. METHODS: The ability of the FCR-1 to detect change in FCR over time was analyzed using a repeated-measures ANOVA and paired-samples t-tests. Pearson correlations were used to measure the concurrent, convergent and discriminant validity of the FCR-1, and a ROC analysis was conducted to determine an optimal clinical cut-off score. RESULTS: The FCR-1 was found to be responsive to change in FCR over time. It demonstrated concurrent validity with the FCRI (r = .395, P = .010), and convergent validity with the Mishel Uncertainty in Illness Scale (r = .493, P = .001) and the Reassurance Questionnaire (r = .325, P = .044). Discriminant validity was confirmed when the FCR-1 did not significantly correlate with unrelated measures. A ROC analysis pinpointed an optimal clinical cut-off score of 45.0. CONCLUSIONS: The FCR-1 is a promising tool that can be incorporated in clinical and research settings. Due to its brevity, the care needs of highly distressed patients can be met quickly and efficiently. In research settings, the FCR-1 can reduce the cognitive burden experienced by survivors.
Keywords:
breast cancer; cancer; fear of cancer recurrence; oncology; psycho-oncology; scale development; single-item measure; survivors; unmet needs; validation
Authors: Lidia Schapira; Yue Zheng; Shari I Gelber; Philip Poorvu; Kathryn J Ruddy; Rulla M Tamimi; Jeffrey Peppercorn; Steven E Come; Virginia F Borges; Ann H Partridge; Shoshana M Rosenberg Journal: Cancer Date: 2021-10-06 Impact factor: 6.921
Authors: Mei Jun Tran; Michael Jefford; Ben Smith; Fiona Lynch; Haryana M Dhillon; Joanne Shaw; Lachlan McDowell; Alan White; Clare Halloran; David Wiesenfeld; Maria Ftanou Journal: Pilot Feasibility Stud Date: 2022-08-10
Authors: Nienke Zomerdijk; Michelle Jongenelis; Camille E Short; Andrew Smith; Jane Turner; Kathryn Huntley Journal: Support Care Cancer Date: 2021-06-23 Impact factor: 3.603